Review: lorazepam provides the best control for status epilepticus

Outcomes Number of trials (n) Comparisons Event rates RRR (95% CI) NNT (CI) Non-cessation of seizures 3 (264) Lorazepam v diazepam 24% v 38% 36% (10 to 55) 8 (5 to 25) 1 (137) Lorazepam v placebo 41% v 79% 48% (29 to 62) 3 (2 to 5) 1 (198) Lorazepam v phenytoin 35% v 56% 38% (14 to 55) 5 (3 to 13) 1 (139) Diazepam v placebo 57% v 79% 27% (8 to 43) 5 (3 to 17) 2 (165) Intrarectal diazepam gel v placebo 32% v 72% 57% (38 to 70) 3 (2 to 4) 1 (39) Intrarectal diazepam gel 30 mg v 20 mg 28% v 71% 61% (14 to 82) 3 (2 to 7) Continuation of status epilepticus requiring a different drug 3 (264) Lorazepam v diazepam 24% v 39% 37% (12 to 55) 7 (4 to 25) 1 (137) Lorazepam v placebo 41% v 79% 48% (29 to 62) 3 (2 to 5) 1 (139) Diazepam v placebo 57% v 79% 27% (8 to 43) 5 (3 to 17) Death 1 (139) Diazepam v placebo 4.4% v 15% 72% (2 to 92) 10 (5 to 100) Ventilatory support 1 (139) Diazepam v placebo 8.8% v 23% 61% (6 to 84) 8 (4 to 50) *Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a fixed effects model.